Hints and tips:
Related Special Reports
...The company is aiming to develop a wide range of drugs and use its manufacturing scale to stay ahead of pharmaceutical rivals seeking to profit from consumer “hype” for weight loss products, he added....
...Zealand’s products in development will have to compete with the popular Wegovy and Zepbound drugs already on the market and made by Novo Nordisk and Eli Lilly respectively, which suppress appetite....
...If the trials approved by the Medicines and Healthcare products Regulatory Agency are successful, the drug will be the first cancer therapy developed on the island of Ireland....
...AstraZeneca is a specialist in cancer treatments, making $17bn and 37 per cent of sales from oncology products in 2023....
...Jeff Emmick, Eli Lilly’s senior vice-president of product development, said that while as many as 80mn US adults may suffer from obstructive sleep apnoea, about a quarter of whom face more serious symptoms...
...“It will encourage them to make sure the medicines are available here and it’s a route for people to get tested with the new medicines in development.”...
...Daiichi Sankyo, which developed the drug with AstraZeneca and leads on marketing of the product in the UK, said it was “extremely disappointed by the decision”....
...Soaring sales of the products have pushed the companies’ valuations to record highs....
...Pharmaceutical companies must replenish their drugs pipeline before exclusivity rights on top-selling products expire....
...Pharmaceutical companies also have a key role to play in providing affordable access to these essential products. The global industry’s response to date has been inadequate and fragmented....
...make up the backbone of pharmaceutical care....
...“But the elegant synthetic design of cresomycin, based on an intuitive rationale, provides an exciting scaffold for further development.”...
...The global contract development and manufacturing market, which supports pharma companies in making products and running clinical trials, is projected to grow from $72bn to $90bn over the next two years,...
...But she said believed new entrants would be able to break into the market “if the product is sufficiently differentiated”....
...Lex has been watching the development of this market closely....
...But Eli Lilly declined to say how much of the product would be available in Britain, or which pharmacies will stock the product. Patients in Northern Ireland will not have access to the pen....
...Zealand expects 10 per cent royalties from any eventual sales of the product....
...“The issue affects anyone developing antifungal drugs because regulatory requirements make the development time for human medicines much longer than for agricultural chemicals,” said Birch....
...Drugs made by Japan’s Eisai and Eli Lilly of the US have shown promise when used early in an individual’s development of the disease....
...The idea of so-called molecular factories harnesses the basic machinery of sustaining life, in which cells constantly turn out biochemical products....
...Despite having a product on the market and being identified by analysts as a potential acquisition target for several large pharmaceutical companies, many European shareholders are still reluctant to invest...
...Spravato, a nasal spray based on a molecule from the psychedelic drug ketamine used to treat depression, already ranks as Johnson & Johnson’s fastest-growing product....
...She urged countries and the pharmaceutical sector to boost funding to tackle nine other high-risk pathogens identified as threats by the WHO....
...GSK has long been a frontrunner in vaccine development, with its shingles jab Shingrix providing £3bn in revenues in 2022....
...Overall, consultants McKinsey estimated in a report in January that AI could generate $60bn-$110bn a year for the pharmaceutical and medical-product industries by identifying compounds for possible new drugs...
International Edition